| Oct 29 |
CervoMed to Deliver Oral Presentation at the 8th International Lewy Body Dementia Conference
|
| Oct 15 |
CervoMed Announces Last Patient Last Visit in Phase 2b RewinD-LB Trial of Neflamapimod for the Treatment of Early-Stage Dementia with Lewy Bodies (DLB)
|
| Oct 4 |
CervoMed Ends $20 Million Stock Sales Agreement with BTIG
|
| Oct 3 |
CervoMed files for $250M mixed securities shelf
|
| Oct 2 |
CervoMed to Participate in 3rd Annual ROTH Healthcare Opportunities Conference
|
| Sep 26 |
CervoMed to Deliver Late-Breaking Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)
|
| Sep 21 |
With 35% ownership, insiders at CervoMed Inc. (NASDAQ:CRVO) are pretty optimistic and have been buying recently
|
| Sep 20 |
CERVOMED INC (CRVO) Soars 10.6%: Is Further Upside Left in the Stock?
|
| Aug 27 |
CervoMed to Participate in Upcoming Investor Conferences
|
| Aug 22 |
CervoMed Featured in Fortune for Advances in the Treatment of Dementia with Lewy Bodies
|
